TC Biopharm’s shares are trending higher in pre-market trading this morning. Up almost 70% trading around $1.07 on heavy volume and more than 16,000 trades.

TC Biopharm (Holdings) PLC (“TC Biopharm” or the “Company”) (NASDAQ: TCBP) (NASDAQ: TCBPW), a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and viral indications, announced today announced the formation of a scientific advisory board (SAB) to advance its gamma-delta T cell therapy, OmnImmune, for the treatment of Acute Myeloid Leukemia (AML).

Company recently announced an offering.

Commercial satellite company lands Government contract and sends shares soaring. Read about this 100% mover with record volume and 346,000 trades.